Iveric Bio, Inc.

Astellas Is Looking For Bolt-On Deals Astellas Pharma is looking to add new assets to its pipeline that could launch in the late 2020s or early in the next decade, chief strategy officer Adam Pearson

Ocuphire Pharma Inc. and privately held Opus Genetics Inc. announced an all-stock merger on 22 October that will create a publicly traded company focused primarily on gene therapies for inherited reti

The developers of Coacillium, vilobelimab, avacincaptad pegol and temozolomide were this week due to provide the European Medicines Agency with oral explanations as to why their respective drugs, whic

Against a background of the globally strengthening R&D focus on rare diseases, Japan is seeing unusually fierce competition in the relatively small indication of Stargardt disease, a rare ophthalmolog